The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | NKG2D-based CAR-T in R/R AML and MDS
CYAD-01 is a natural killer group 2D (NKG2D)-based CAR T-cell product. David Sallman, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses the latest results from the completed dose-escalation of the hematological arm of the phase I THINK study (NCT03018405), which evaluated the safety and clinical activity of multiple infusions CYAD‑01 without any prior preconditioning chemotherapy in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
